Government
As the number of diagnosed cases of COVID-19 continues to rise in the United States, Eli Lilly has partnered with the Indiana State Department of Health to accelerate testing for the virus in that state.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The U.S. National Institutes of Health announced that a Phase II clinical trial of AstraZeneca and Merck’s selumetinib in neurofibromatosis type 1 shrank inoperable tumors.
The U.S. Food and Drug Administration approved Abbott’s molecular test for the novel coronavirus that causes COVID-19 under an Emergency Use Authorization.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
As the world shifts toward a concept of social distancing as part of an attempt to protect against the novel coronavirus, new research is showing the virus that causes COVID-19 is quite stable on hard surfaces, and even in the air.
The U.S. Food and Drug Administration granted Eli Lilly and Company and Incyte Corporation Breakthrough Therapy designation for baricitinib for alopecia areata.
A bill to encourage the manufacture of active pharmaceutical ingredients in America was introduced in the U.S. Senate Tuesday by Senators Marsha Blackburn (R- TN) and Bob Menendez (D- NJ).
The U.S. Food and Drug Administration has two PDUFA dates this week, one for a type of epilepsy and the other for a triple-combination drug for cystic fibrosis. Here’s a look.
Hospitals and laboratories will be able to run the test on Roche’s fully automated cobas 6800 and cobas 8800 Systems, which are already in wide use in the U.S. and internationally.
PRESS RELEASES